ReviewAging2021
Growth differentiation factor 11: a "rejuvenation factor" involved in regulation of age-related diseases?
Review in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Kill two birds with one stone: Reprogramming tumor microenvironment with growth differentiation factor 11.World journal of gastroenterology · 2026Article
- Association of serum growth differentiation factor 11 with asthma severity, inflammation, and airway remodeling in pediatric patients.Frontiers in medicine · 2026Article
- GDF11-secreting cell transplant efficiently ameliorates age-related pulmonary fibrosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- A Frailty-Based Plasma Proteomic Signature Capturing Overall Health and Well-Being in Older Adults.Aging cell · 2025Article
- Systemic factors in young human serum influenceAging · 2025Article
- The influence of the geroprotective cytokine on the transcriptome of young and senescent mesenchymal stem cells.BMC research notes · 2025Article
- Association of ageing-related biomarkers with peripheral neuropathy in colorectal cancer patients up to 2 years after diagnosis.PloS one · 2025Article
- Analysis of prevalence and associated biomarkers of sarcopenia in older adults living in rural community in Wuhan, China.Frontiers in endocrinology · 2025Article
- Natural saponins and macrophage polarization: Mechanistic insights and therapeutic perspectives in disease management.Frontiers in pharmacology · 2025Review
- GDF11: An emerging therapeutic target for liver diseases and fibrosis.Journal of cellular and molecular medicine · 2024Review
- GDF-11 downregulates placental human chorionic gonadotropin expression by activating SMAD2/3 signaling.Cell communication and signaling : CCS · 2023Article
- Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases.Signal transduction and targeted therapy · 2023Review
- GDF11 reverses mood and memory declines in aging.Nature aging · 2023Article
- TGF-β pathways in aging and immunity: lessons fromFrontiers in genetics · 2023Review
- Potential Satellite Cell-Linked Biomarkers in Aging Skeletal Muscle Tissue: Proteomics and Proteogenomics to Monitor Sarcopenia.Proteomes · 2022Review
- GDF-11 promotes human trophoblast cell invasion by increasing ID2-mediated MMP2 expression.Cell communication and signaling : CCS · 2022Article
- Novel Epigenetic Clock Biomarkers of Age-Related Macular Degeneration.Frontiers in medicine · 2022Article
- Exosomes and Micro-RNAs in Aging Process.Biomedicines · 2021Review
- Loss of Growth Differentiation Factor 11 Shortens Telomere Length by Downregulating Telomerase Activity.Frontiers in physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth differentiation factor 11 (GDF11), a member of the transforming growth factor β superfamily of cytokines, is a critical rejuvenation factor in aging cells. GDF11 improves neurodegenerative and neurovascular disease outcomes, increases skeletal muscle volume, and enhances muscle strength. Its wide-ranging biological effects may include the reversal of senescence in clinical applications, as well as the ability to reverse age-related pathological changes and regulate organ regeneration after injury. Nevertheless, recent data have led to controversy regarding the functional roles of GDF11, because the underlying mechanisms were not clearly established in previous studies. In this review, we examine the literature regarding GDF11 in age-related diseases and discuss potential mechanisms underlying the effects of GDF11 in regulation of age-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.